UroGen Pharma URGN Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$23.57M+46.2% | -$26.36M+29.7% | -$33.35M-40.9% | -$49.94M-49.5% | -$43.84M-35.8% | ||
| $75K+4.2% | $75K+10.3% | $100K0.0% | $100K0.0% | $72K-41.5% | ||
| $4.63M+50.8% | $3.13M-5.2% | $3.03M-13.2% | $2.73M-23.2% | $3.07M+11.4% | ||
| $22.33M+3,463% | $13.38M— | —— | —— | -$664K+48.3% | ||
| $4.46M+372% | $8.12M+397% | $1.21M+698% | -$462K-332% | -$1.64M-204% | ||
| $7.63M+164% | $1.54M-80.1% | -$4.79M— | $640K-88.6% | $2.89M+78.5% | ||
| -$3.68M-2.1% | $2.4M— | —— | $4.68M— | -$3.6M+38.2% | ||
| $2.33M+1,170% | —— | $5.96M+2,066% | $430K+201% | -$218K+76.8% | ||
| $0-100% | -$1K-100% | -$263K— | -$421K— | $483K— | ||
| $577K+35.8% | $604K+154% | $559K+182% | $516K+167% | $425K+86.4% | ||
| -$53K+92.8% | —— | -$628K-241% | -$606K-211% | -$738K-199% | ||
| $1.97M+428% | $99K— | —— | $400K— | $374K+139% | ||
| -$45.32M-7.8% | -$38.33M-181% | -$42.27M-52.8% | -$39.83M-67.7% | -$42.02M-32.4% | ||
| $54K+22.7% | $17K-85.2% | $87K-9.4% | $141K+67.9% | $44K— | ||
| $4.15M-89.7% | $28.27M-59.6% | $40.21M+231% | $30.34M+151% | $40.43M+199% | ||
| -$20.69M+20.3% | $27.72M— | $31.4M+129% | $28.41M+137% | -$25.96M-292% | ||
| $65.35M— | $0-100% | —— | —— | $0-100% | ||
| $0-100% | $31.83M— | $7.97M-46.9% | -$4K-100% | $4K-100.0% | ||
| —— | $463.75K— | $463.75K— | $463.75K— | $463.75K— | ||
| $65.2M+191,676% | $31.32M+44,007% | $8.27M-79.1% | $296K-99.7% | $34K-99.9% | ||
| -$800K+98.8% | —— | -$2.6M— | -$11.12M-113% | -$67.95M-286% | ||
| -$26K-103% | $75K-94.4% | $160K-85.1% | $866K+191% | $774K+323% | ||
| $1.97M+428% | $99K— | —— | $400K— | $374K+139% | ||
| -$3.68M-2.1% | $2.4M— | —— | $4.68M— | -$3.6M+38.2% | ||
| -$53K+92.8% | —— | -$628K-241% | -$606K-211% | -$738K-199% | ||
| $0-100% | -$1K-100% | -$263K— | -$421K— | $483K— | ||
| $4.86M+17.4% | $2.55M+149% | $67K-96.4% | —— | $4.14M+1,870% | ||
| $577K+35.8% | $604K+154% | $559K+182% | $516K+167% | $425K+86.4% | ||
| $4.15M-89.7% | $28.27M-59.6% | $40.21M+231% | $30.34M+151% | $40.43M+199% | ||
| —— | $463.75K— | $463.75K— | $463.75K— | $463.75K— | ||
| $1.06M+156% | $1.27M-79.1% | $1.47M-52.1% | $2.01M-39.8% | -$1.89M-173% | ||
| $321K— | —— | —— | —— | -$0— | ||
| -$53K+92.8% | —— | -$628K-241% | -$606K-211% | -$738K-199% | ||
| —— | $28K-81.2% | $28K-81.2% | $28K-81.2% | $28K-81.2% | ||
| $0-100% | —— | —— | —— | $3.13M— | ||
| $60K-97.1% | $571K-75.4% | $3.5M— | $1.31M— | $2.05M— | ||
| $0-100% | —— | —— | —— | $3.13M— | ||
| -$45.37M-7.8% | -$38.34M-179% | -$42.36M-52.6% | -$39.97M-67.7% | -$42.07M-32.6% | ||
| -$45.37M-7.8% | -$38.34M-179% | -$42.36M-52.6% | -$39.97M-67.7% | -$42.07M-32.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does UroGen Pharma's cash flow data come from?
- Every line is extracted from UroGen Pharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.